‘NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer’ of page ‘NRG-GI002’
Principal Investigator Thomas George, MD Primary Objective To demonstrate an absolute improvement in Neoadjuvant Rectal Cancer (NAR) score for the experimental regimen as compared to control. Patient Population Patients with tumor clinically determined to be locally advanced Stage II or Stage III rectal cancer, defined as meeting any one of the following criteria: distal location […]
Read More